Zomedica Stock Buy Hold or Sell Recommendation

ZOM Stock  USD 0.20  0.01  5.26%   
Considering the 90-day investment horizon and your complete indifference towards market risk, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Hold'. Macroaxis provides Zomedica Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZOM positions. The advice algorithm takes into account all of Zomedica Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from Zomedica Pharmaceuticals' buy-and-hold perspective. Check out Zomedica Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Zomedica and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices.

Execute Zomedica Pharmaceuticals Buy or Sell Advice

The Zomedica recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zomedica Pharmaceuticals Corp. Macroaxis does not own or have any residual interests in Zomedica Pharmaceuticals Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zomedica Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Zomedica PharmaceuticalsBuy Zomedica Pharmaceuticals
Buy

Market Performance

Details

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Details

Financial Strenth (F Score)

Details

Financial Leverage

Inapplicable
Details

Reporting Quality (M-Score)

Details
For the selected time horizon Zomedica Pharmaceuticals Corp has a Risk Adjusted Performance of (0.07), Jensen Alpha of (0.31), Total Risk Alpha of (0.23) and Treynor Ratio of (0.24)
We provide recommendation to complement the prevalent expert consensus on Zomedica Pharmaceuticals. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Zomedica Pharmaceuticals Corp is not overpriced, please check out all Zomedica Pharmaceuticals fundamentals, including its ebitda and the relationship between the current ratio and net asset . As Zomedica Pharmaceuticals appears to be a penny stock we also urge to confirm its number of shares shorted numbers.

Zomedica Pharmaceuticals Trading Alerts and Improvement Suggestions

Zomedica Pharmaceuticals generated a negative expected return over the last 90 days
Zomedica Pharmaceuticals has some characteristics of a very speculative penny stock
Zomedica Pharmaceuticals has high historical volatility and very poor performance
The company reported the last year's revenue of 18.93 M. Reported Net Loss for the year was (17.02 M) with profit before taxes, overhead, and interest of 13.65 M.
Zomedica Pharmaceuticals Corp has about 27.4 M in cash with (11.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19.
Zomedica Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Veterinary Oncology Global Market Report 2023 - GlobeNewswire

Zomedica Pharmaceuticals Returns Distribution Density

The distribution of Zomedica Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Zomedica Pharmaceuticals' future price movements. The chart of the probability distribution of Zomedica Pharmaceuticals stock daily returns describes the distribution of returns around its average expected value. We use Zomedica Pharmaceuticals Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zomedica Pharmaceuticals returns is essential to provide solid investment advice for Zomedica Pharmaceuticals.
Mean Return-0.34Value At Risk-5
Potential Upside5.00Standard Deviation3.94
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zomedica Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Zomedica Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Zomedica Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors.are aggressively trading Zomedica Pharmaceuticals Corp backward and forwards among themselves. Zomedica Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Zomedica Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Last TransactionTypeSharesValue
Vanguard Group Inc2023-03-31Common Shares49 M10.4 M
Cambridge Investment Research Advisors Inc2023-03-31Common Shares11.3 M2.4 M
Blackrock Inc2023-03-31Common Shares10.2 M2.2 M
Geode Capital Management Llc2023-03-31Common Shares9.3 MM
State Street Corp2023-03-31Common Shares3.3 M703.2 K
Brown Brothers Harriman Co2023-03-31Common Shares2.3 M483.8 K
Proshare Advisors Llc2023-03-31Common Shares2.1 M451.1 K
Northern Trust Corp2023-03-31Common Shares1.8 M374.8 K
Gsa Capital Partners Llp2022-06-30Common Shares1.3 M280 K
Pinnacle Wealth Management Group Inc2023-03-31Common Shares972.3 K205.8 K
Jane Street Group Llc2023-03-31Common Shares948 K200.7 K
Note, although Zomedica Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Zomedica Pharmaceuticals Cash Flow Accounts

201820192020202120222023 (projected)
Capital Expenditure(619 K)(155.51 K)5.55 K(147 K)(2.55 M)(2.62 M)
Depreciation Amortization and Accretion203.68 K786.53 K305.91 K265 K426 K399.99 K
Net Cash Flow or Change in Cash and Cash Equivalents(1.51 M)(1.43 M)61.48 M132.96 M(167.54 M)(171.95 M)
Issuance Purchase of Equity Shares10.26 M2.29 M52.38 M187.02 M215.08 M232.06 M
Net Cash Flow from Financing10.26 M14.89 M76.71 M219.16 M8 K8.21 K
Net Cash Flow from Investing(619 K)(686.93 K)1.01 M(71.92 M)(155.88 M)(159.98 M)
Net Cash Flow from Operations(11.15 M)(15.63 M)(16.24 M)(14.28 M)(11.67 M)(12.59 M)
Share Based Compensation5.66 M3.33 M1.66 M7.09 M7.89 M6.49 M

Zomedica Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zomedica Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zomedica Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zomedica stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
-0.31
β
Beta against NYSE Composite1.44
σ
Overall volatility
3.97
Ir
Information ratio -0.08

Zomedica Pharmaceuticals Volatility Alert

Zomedica Pharmaceuticals Corp exhibits very low volatility with skewness of -1.32 and kurtosis of 4.45. However, we advise investors to further study Zomedica Pharmaceuticals Corp technical indicators to ensure that all market info is available and is reliable. Zomedica Pharmaceuticals Corp is a potential penny stock. Although Zomedica Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Zomedica Pharmaceuticals Corp. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Zomedica instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Zomedica Pharmaceuticals Fundamentals Vs Peers

Comparing Zomedica Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zomedica Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Zomedica Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zomedica Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zomedica Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Zomedica Pharmaceuticals to competition
FundamentalsZomedica PharmaceuticalsPeer Average
Return On Equity(0.07) %(0.31) %
Return On Asset(0.06) %(0.14) %
Profit Margin(0.94) %(1.27) %
Operating Margin(1.22) %(5.51) %
Current Valuation71.77 M16.62 B
Shares Outstanding979.95 M571.82 M
Shares Owned by Insiders1.33 %10.09 %
Shares Owned by Institutions9.77 %39.21 %
Number of Shares Shorted70.02 M4.71 M
Price to Book0.70 X9.51 X
Price to Sales11.10 X11.42 X
Revenue18.93 M9.43 B
Gross Profit13.65 M27.38 B
EBITDA(15.19 M)3.9 B
Net Income(17.02 M)570.98 M
Cash and Equivalents27.4 M2.7 B
Cash per Share0.19 X5.01 X
Total Debt1.1 M5.32 B
Debt to Equity0.006 %48.70 %
Current Ratio43.50 X2.16 X
Book Value Per Share0.27 X1.93 K
Cash Flow from Operations(11.67 M)971.22 M
Short Ratio21.14 X4.00 X
Earnings Per Share(0.02) X3.12 X
Target Price0.44
Number of Employees8518.84 K
Beta0.95-0.15
Market Capitalization190.6 M19.03 B
Total Asset279.61 M29.47 B
Retained Earnings(136.4 M)9.33 B
Working Capital115.69 M1.48 B
Net Asset279.61 M
Note: Purchase by Johnny Powers of 100000 shares of Zomedica Pharmaceuticals [view details]

Zomedica Pharmaceuticals Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zomedica . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Zomedica Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Zomedica Pharmaceuticals Corp? Buying financial instruments such as Zomedica Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2020 2021 2022 2023 (projected)
Current Assets63.87 M200.41 M123.5 M98.19 M
Total Assets66.14 M280.4 M279.61 M301.68 M

Use Investing Ideas to Build Portfolios

In addition to having Zomedica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alternative Energy Thematic Idea Now

Alternative Energy
Alternative Energy Theme
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
View All  Next Launch
Check out Zomedica Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.02) 
Revenue Per Share
0.021
Quarterly Revenue Growth
0.461
Return On Assets
(0.06) 
Return On Equity
(0.07) 
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.